(Q37723842)

22 August 2017

Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. (English)

1 reference

22 August 2017

Eva Hellström-Lindberg

4

object named as

Eva Hellström-Lindberg

0 references

Pierre Fenaux

2

object named as

Pierre Fenaux

1 reference

22 August 2017

Valeria Santini

1

1 reference

22 August 2017

Ghulam J Mufti

3

1 reference

22 August 2017

Eva Hellström-Lindberg

4

1 reference

22 August 2017

Lewis R Silverman

5

1 reference

22 August 2017

Alan List

6

1 reference

22 August 2017

Steven D Gore

7

1 reference

22 August 2017

John F Seymour

8

1 reference

22 August 2017

Jay Backstrom

9

1 reference

22 August 2017

Charles L Beach

10

1 reference

22 August 2017

language of work or name

1 reference

12 April 2010

1 reference

European Journal of Haematology

22 August 2017

1 reference

22 August 2017

85

1 reference

22 August 2017

2

1 reference

22 August 2017

130-138

1 reference

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000014

Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000014

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000014

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000014

International scoring system for evaluating prognosis in myelodysplastic syndromes

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000014

The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000014

Improving survival in myelodysplastic syndromes

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000014

Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000014

Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000014

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000014

Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes

1 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20394651

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1600-0609.2010.01456.X

1 reference

22 August 2017

1 reference

22 August 2017

PubMed publication ID

20394651

1 reference